Gilead Sciences (GILD) Reports Positive Phase 3 IDEAL Results for Livdelzi in PBC

Gilead Sciences Inc. (NASDAQ:GILD) is one of the most undervalued quality stocks to invest in. On June 2, Gilead Sciences announced positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in patients with primary biliary cholangitis/PBC. The study showed statistically significant improvements in composite alkaline phosphatase/ALP normalization compared with placebo after 52 weeks.

The trial evaluated patients with inadequately controlled PBC, including those with elevated ALP levels or intolerance to ursodeoxycholic acid/UDCA. Results demonstrated that a higher proportion of patients achieved sustained ALP normalization, with a safety profile consistent with previous studies and no new safety concerns identified.

Gilead Sciences (GILD) Reports Positive Phase 3 IDEAL Results for Livdelzi in PBC

Gilead said the findings strengthen evidence supporting ALP normalization as a key treatment goal in PBC and expand understanding of Livdelzi’s clinical benefit across a broader patient population. The company also noted that full results will be presented at an upcoming medical congress and shared with regulatory authorities for further review.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1